Status:
COMPLETED
PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer
Lead Sponsor:
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborating Sponsors:
Celgene
Conditions:
Pancreatic Adenocarcinoma
Eligibility:
All Genders
18+ years
Brief Summary
Due to the generally poor prognosis, with no chance of long-term survival, health related quality of life is a very important objective in the treatment of patients with pancreatic cancer. The non-int...
Detailed Description
Pancreatic cancer is often diagnosed at an advanced stage, because most of the patients have no symptoms until the cancer metastasized. In the majority of study cases pancreatic cancer research focuse...
Eligibility Criteria
Inclusion
- Written informed consent and signed data protection form before any study specific intervention, including screening, will be done
- Age ≥ 18 years
- Histologically or cytologically confirmed pancreatic adenocarcinoma
- Systemic neoadjuvant, adjuvant, 1st line systemic therapy is planned or recently started (within last 14 days)
Exclusion
- Patients who are unable to consent because they do not understand the nature, significance and implications of the study
- Patients who are unable to understand or fill out the QoL survey
- Patients in 2nd or further treatment lines that have not been documented for 1st line therapy within the study
Key Trial Info
Start Date :
October 24 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2023
Estimated Enrollment :
469 Patients enrolled
Trial Details
Trial ID
NCT04119362
Start Date
October 24 2019
End Date
June 30 2023
Last Update
March 7 2024
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
HELIOS Klinikum Bad Saarow
Bad Saarow, Germany, 15526
2
MVZ am Oskar-Helene-Heim
Berlin, Germany
3
Klinikum Coburg
Coburg, Germany
4
Onkozentrum Dresden/Freiberg
Dresden, Germany